Atorvastatin Drug Market - Introduction
- Atorvastatin is a class of prescription medicine called HMG-CoA reductase inhibitors (statins), which lowers the low density proteins (LDL) cholesterol and triglycerides in the blood.
- Atorvastatin works by reducing the production of cholesterol in the body to reduce the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Atorvastatin help prevent heart attacks, atherosclerosis, and also have significant anti-inflammatory effects.
- Atorvastatin, lovastatin, pitavastatin, rosuvastatin, and simvastatin are the common types of statins available in the market
Atorvastatin Drug Market- Drivers, Retrains, Trends
- Increase in prevalence of hypercholesterolemia is a key factor driving the market. Moreover, an increase in adoption of combination therapies that utilize statins with other cholesterol diminishing compounds, such as ezetimibe, is projected to boost the market.
- Improving healthcare infrastructure and growing health awareness among consumers are other factors that drive the market
- Following unhealthy lifestyles, an increase in saturated and trans-fat intake, and reduced indulgence in physical activities are expected to fuel the atorvastatin drug market. Furthermore, a rise in smoking and alcohol intake that enhances the risk of elevated cholesterol level is another factor propelling the market.
- The factors that are likely to contribute to the dominance of atorvastatin in India is highly privatized healthcare system such as that in the U.S., where pharmaceutical companies provide financial incentives to hospitals to prescribe their drugs. However, in countries such as India, manufacturers market their products profoundly to physicians and pharmacists.
- Rise in preference for alternative medicines in emerging regions such as North America is a major factor restraining the stains market. Moreover, worsening socioeconomic conditions are anticipated to further restrain the market. No healthcare insurance in countries such as India and the price capping by pricing authorities are other limiting factor for the atorvastatin market.
- Organizations are extending business across the globe by introducing efficient delivery channels, particularly in developed countries, certain features are projected to generate lucrative growth opportunities for the market
North America to Dominate Global Atorvastatin Market
- In terms of region, the global statin market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is projected to dominate the global atorvastatin market.
- Well-established healthcare infrastructure, hub for key industry players, and early adoption of technologically advanced products are key factors that are projected to fuel the market in North America in the next few years
- Asia Pacific is also expected to hold a significant share of the global market, due to an increase in healthcare awareness, research activities, and government initiatives in the healthcare sector in the region
Key players operating in the atorvastatin market are
- Pfizer
- AstraZeneca
- Merck & Co.
- Novartis AG
- Abbvie
- Dr. Reddy’s
- Sun Pharmaceuticals Industries Ltd.
- Sanofi
- Abbott
These prominent players are using strategies such as mergers & acquisitions, mergers, contracts & collaborations. These strategies would deliver high-performance goods, better client satisfaction, and supporting market laws.
Atorvastatin Drug Market – Research Scope
Global Atorvastatin Drug Market, by Type
- Natural Statins.
- Synthetic Statins.
Global Atorvastatin Drug Market, by Drug Class
- Atorvastatin
- Lovastatin
- Pravastatin
- Fluvastatin
- Simvastatin
- Others
Global Atorvastatin Drug Market, by Therapeutic Area
- Cardiovascular disorders
- Lifestyle diseases
- Obesity
- Inflammatory disorders
Global Atorvastatin Drug Market, by Application
Global Atorvastatin Drug Market, by Distribution
Global Atorvastatin Drug Market, by Region
- North America
- Asia Pacific
- China
- Australia
- Japan
- India
- South Korea
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East & Africa
Interested in this report?
Get a FREE Brochure now!